ArticleNature2019
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Erratum issued 2 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 598 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
598citing papers in PubMed, 1 pooled it
39.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data
NCT06224049 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation
A Clinical Study to Evaluate the Safety, Tolerability and Initial Efficacy of Targeted Haploidentical Neoantigen T Cell Injection (hNeo-T) in the Treatment of Relapsed or Refractory EBV-positive T-cell Lymphoma
Who cites it
598 citing papers in PubMed, 1 synthesis or guideline pooled it, 910 citations in OpenAlex.
- Targeted agents in patients with progressive glioblastoma-A systematic meta-analysis of randomized clinical trials.Cancer medicine · 2024Pooled it
- TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.Nature communications · 2025Trial
- A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.Neuro-oncology · 2024Trial
- Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.Frontiers in immunology · 2024Trial
- Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.Oncoimmunology · 2026Article
- Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8Molecular therapy. Nucleic acids · 2026Article
- Immunotherapy for Newly Diagnosed Glioblastoma: Current Evidence and Future Perspectives.Journal of personalized medicine · 2026Review
- Review
- Developing neoantigen cancer vaccines: where are we now?Nature communications · 2026Review
- Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- Combining Radiation-Treated Tumor Vaccines With Mn-MOF Nanoadjuvants to Amplify Radiation Induced Anti-Tumor Immune Responses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.Nature cancer · 2026Article
- Review
- Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.NPJ precision oncology · 2026Review
- Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.Nature cancer · 2026Article
- A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations.Cancer research · 2026Article
- Immunopeptidomics-guided identification of functional neoantigens in non-small cell lung cancer.NPJ precision oncology · 2026Article
- Cancer immunotherapy: mechanisms, clinical applications, resistance and future directions.Molecular biology reports · 2026Review
- Review
538 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
64 authors at 19 institutions in 8 countries.
Norbert Hilf *Immatics Biotechnologies GmbH, Tübingen, Germany.
Sabrina Kuttruff-Coqui *Immatics Biotechnologies GmbH, Tübingen, Germany.
Katrin FrenzelBioNTech AG, Mainz, Germany.
Valesca BukurBioNTech AG, Mainz, Germany.
Stefan StevanovićEberhard Karls Universität Tübingen, Tübingen, Germany.
Cécile GouttefangeasEberhard Karls Universität Tübingen, Tübingen, Germany.
Michael PlattenUniversity Hospital Heidelberg, Heidelberg, Germany.
Ghazaleh TabatabaiEberhard Karls Universität Tübingen, Tübingen, Germany.
Valerie DutoitGeneva University Hospital, Geneva, Switzerland.
Sjoerd H van der BurgCIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Per Thor StratenCIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Francisco Martínez-RicarteVall d'Hebron University Hospital, Barcelona, Spain.
Berta PonsatiBCN Peptides SA, Barcelona, Spain.
Hideho OkadaUniversity of California, San Francisco, San Francisco, CA, USA.
Ulrik LassenRinghospitalet, Copenhagen, Denmark.
Arie AdmonTechnion - Israel Institute of Technology, Haifa, Israel.
Christian H OttensmeierUniversity of Southampton, Southampton, UK.
Alexander UlgesImmatics Biotechnologies GmbH, Tübingen, Germany.
Sebastian KreiterBioNTech AG, Mainz, Germany.
Andreas von DeimlingUniversity Hospital Heidelberg, Heidelberg, Germany.
Marco SkardellyUniversity Hospital Tübingen, Tübingen, Germany.
Denis MiglioriniGeneva University Hospital, Geneva, Switzerland.
Judith R KroepLeiden University Medical Center, Leiden, The Netherlands.
Manja IdornCenter for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark.
Jordi RodonVall d'Hebron University Hospital, Barcelona, Spain.
Jordi PiróBCN Peptides SA, Barcelona, Spain.
Hans S PoulsenRinghospitalet, Copenhagen, Denmark.
Bracha ShraibmanTechnion - Israel Institute of Technology, Haifa, Israel.
Katy McCannUniversity of Southampton, Southampton, UK.
Regina MendrzykImmatics Biotechnologies GmbH, Tübingen, Germany.
Martin LöwerBioNTech AG, Mainz, Germany.
Monika StieglbauerEberhard Karls Universität Tübingen, Tübingen, Germany.
Cedrik M BrittenBioNTech AG, Mainz, Germany.
David CapperUniversity Hospital Heidelberg, Heidelberg, Germany.
Marij J P WeltersCIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Juan SahuquilloVall d'Hebron University Hospital, Barcelona, Spain.
Katharina KieselImmatics Biotechnologies GmbH, Tübingen, Germany.
Evelyna DerhovanessianBioNTech AG, Mainz, Germany.
Elisa RuschEberhard Karls Universität Tübingen, Tübingen, Germany.
Lukas BunseUniversity Hospital Heidelberg, Heidelberg, Germany.
Colette SongImmatics Biotechnologies GmbH, Tübingen, Germany.
Sandra HeeschBioNTech AG, Mainz, Germany.
Claudia WagnerImmatics Biotechnologies GmbH, Tübingen, Germany.
Alexandra Kemmer-BrückBioNTech AG, Mainz, Germany.
Jörg LudwigImmatics Biotechnologies GmbH, Tübingen, Germany.
John C CastleBioNTech AG, Mainz, Germany.
Oliver SchoorImmatics Biotechnologies GmbH, Tübingen, Germany.
Arbel D TadmorTRON GmbH - Translational Oncology at the University Medical Center of Johannes Gutenberg University, Mainz, Germany.
Edward GreenGerman Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
Jens FritscheImmatics Biotechnologies GmbH, Tübingen, Germany.
Miriam MeyerImmatics Biotechnologies GmbH, Tübingen, Germany.
Nina PawlowskiImmatics Biotechnologies GmbH, Tübingen, Germany.
Sonja DornerImmatics Biotechnologies GmbH, Tübingen, Germany.
Franziska HoffgaardImmatics Biotechnologies GmbH, Tübingen, Germany.
Bernhard RösslerImmatics Biotechnologies GmbH, Tübingen, Germany.
Dominik MaurerImmatics Biotechnologies GmbH, Tübingen, Germany.
Toni WeinschenkImmatics Biotechnologies GmbH, Tübingen, Germany.
Carsten ReinhardtImmatics Biotechnologies GmbH, Tübingen, Germany.
Christoph HuberBioNTech AG, Mainz, Germany.
Hans-Georg RammenseeEberhard Karls Universität Tübingen, Tübingen, Germany.
Harpreet Singh-JasujaImmatics Biotechnologies GmbH, Tübingen, Germany.
Ugur SahinBioNTech AG, Mainz, Germany.
Pierre-Yves DietrichGeneva University Hospital, Geneva, Switzerland.
Wolfgang WickUniversity Hospital Heidelberg, Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de.
Immatics Biotechnologies (Germany) · DEBioNTech (Germany) · DEGerman Cancer Research Center · DEHeidelberg University · DELeiden University Medical Center · NLUniversity Hospital of Geneva · CHRigshospitalet · DKTechnion – Israel Institute of Technology · ILUniversity Children's Hospital Tübingen · DEUniversity Hospital Heidelberg · DEUniversity of Copenhagen · DKUniversity of Southampton · GBUniversity of Tübingen · DEVall d'Hebron Hospital Universitari · ESCharité - Universitätsmedizin Berlin · DEGlaxoSmithKline (United Kingdom) · GBJohannes Gutenberg University Mainz · DEThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · US
Funding
Cancer Research UK 15951Medical Research Council MR/P024351/1
Abstract
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors
Indexed as
AdultAgedAntigens, NeoplasmCancer VaccinesCD8-Positive T-LymphocytesEpitopes, T-LymphocyteFemaleGlioblastomaHLA-A AntigensHumansImmunologic MemoryMaleMiddle AgedPrecision MedicineT-Lymphocytes, Helper-InducerTreatment OutcomeAntigens, NeoplasmCancer VaccinesEpitopes, T-LymphocyteHLA-A Antigens
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04792437ClinicalTrials.gov
NCT06224049ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.